Acromegaly and comorbid conditions. New possibilities of diagnosis and treatment (literature review)

Cover Page

Cite item

Full Text

Abstract

Based on the data published in Russian and foreign reference sources, an analysis of clinical-hormonal peculiarities, modern methods of treatment of acromegaly combined with polyendocrinopathies (diabetes mellitus, diffuse and nodular goiter, hypocorticoidism) and cardiovascular diseases was conducted. According to different authors, a decline in the quality and duration of life of patients is associated with significant changes in the endocrine system caused by contrainsular and stimulating effect of somatotropic hormone (STH) and insulin-like growth factor 1 (IGF-1) on organs and tissues. Secondary diabetes mellitus was identified in 16-46% of patients, nodular goiter in 30-70%, secondary adrenal insufficiency in 11-20% of patients. The most common cause of acromegaly is an active pituitary tumor – somatotropinoma, rarely STH is overproduced by neuroendocrine cells, located endo- and extracranially. Recent achievements in neuroendocrinology provided significant improvement of management of patients. The aim of treatment for acromegaly is to achieve clinical and biochemical remission of the disease. At present three basic methods of treatment for acromegaly are used: surgical (endonasal transsphenoidal adenomectomy), drug therapy, radiation therapy and stereotactic radiosurgery (cyber knife). Differential and combined use of modern medical drugs in the form of monotherapy and in a combination with surgical and radiation treatment permits to achieve both clinical and hormonal remission of acromegaly improving in this way the quality and duration of life of patients. In the given review of literature modern concepts of etiology, pathogenesis, clinical peculiarities, modern methods of diagnosis and treatment of this disease are presented.

About the authors

A. U. Zhulidova

Ryazan State Medical University

Author for correspondence.
Email: anya.zhulidova@yandex.ru
ORCID iD: 0000-0003-1381-1884
SPIN-code: 2012-8600

PhD Student of the Department of Faculty Therapy with a Course of Endocrinology, Clinical Pharmacology and Occupational Diseases

Russian Federation, 9, Vysokovoltnaja, Ryazan, 390026

I. I. Dubinina

Ryazan State Medical University

Email: anya.zhulidova@yandex.ru
ORCID iD: 0000-0001-6726-1756

MD, Grand PhD, Professor of the Department of Faculty Therapy with a Course of Endocrinology

Russian Federation, 9, Vysokovoltnaja, Ryazan, 390026

References

  1. Dedov II, Molitvoslovova NN, Roghin-skaya LY, et. al. Federal’nye klinicheskie rekomendacii po klinike, diagnostike, differencial’noj diagnostike i metodam lechenija acromegalii. Problems of endocrinology. 2013; 59(6):4-18. (In Russ).
  2. Antsiferov MB, Alekseeva TM, Pronin VS. Moskovskiy registr bol'nykh akromegaliey: otdalennye rezul'taty nablyudeniya. Farmateka. 2016; 16(329):62-6. (In Russ).
  3. Blagosklonnaya YaV, Shlyakhto EV, Babenko AYu. Endokrinologiya: uchebnik dlya meditsinskikh vuzov. 2nd ed. Saint-Petersburg: SpecLit; 2007. (In Russ).
  4. Dedov II, Melnichenko GA, Marova EI. Akromegaliya: patogenez, klinika, diagnostika, differentsial'naya diagnostika, metody lecheniya: posobie dlya vrachey. Tver': Triada; 2003. (In Russ).
  5. Potemkin VV, Pronin VS. Gipofi-zarnyy gigantizm i akromegaliya. In: Potemkin VV, editor. Endokrinologiya: rukovodstvo dlya vrachey. Moscow: MIA; 2013. (In Russ).
  6. Dedov II, Mel'nichenko GA. Endo-krinologiya: natsional'noe rukovodstvo. Moscow: GEOTAR-Media; 2013. (In Russ).
  7. Pronin VS. Diagnosticheskie i prognosticheskie faktory, opredelyayushchie osobennosti klinicheskogo techeniya i taktiku lecheniya akromegalii [dissertation]. Moscow; 2011. Available at: http://medical-diss.com/medicina/diagnosticheskie-i-progno-sticheskie-faktory-opredelyayuschie-osoben-nosti-klinicheskogo-techeniya-i-taktiku-leche-niya-akro-1. Accessed: 1 Feb 2018. (In Russ).
  8. Ilovayskaya IA. Kardiologicheskie oslozhneniya akromegalii. Farmateka. 2009; 10:25-31. (In Russ).
  9. Egorova NA, Khalimov YuSh, Niki forov VS, et al. Vzaimosvyaz' pokazateley sutochnogo monitorirovaniya arterial'nogo davleniya i gormonal'noy aktivnosti so strukturno-funktsional'nymi kharakteristikami miokarda u bol'nykh akromegaliey v zavisi-mosti ot nalichiya arterial'noy gipertenzii Arterial Hypertension. 2011;17(2):141-5. (In Russ).
  10. Zav'yalova YuV, Borovikov NN, Zanozina OV. Analiz sutochnogo monito-rirovaniya arterial'nogo davleniya u bol'nykh s somatotropinomoy. Arkhiv" vnutrenney meditsiny. 2014; 3(17): 52-4. (In Russ).
  11. Dreval' AV, Trigolosova IV, Vinogradova AV, et al. Narusheniya ugle-vodnogo obmena pri akromegalii: posobie dlya vrachey. Moscow; 2012. (In Russ).
  12. Trigolosova IV, Vinogradova AV, Kruglyakova MV. Sakharnyy diabet pri neyroendokrinnykh zabolevaniyakh. Almanac of clinical medcine. 2014;32:89-96. (In Russ).
  13. Petrik GG, Pavlishchuk SA. Vliya-nie khronicheskoy giperglikemii na pa-ramet-ry belkovogo, lipidnogo obmenov i trombot-sitarno-koagulyatsionnogo gemostaza pri ak-romegalii. Obesity and metabolism. 2011; 4:24-7. (In Russ).
  14. Molitvoslovova NN, Peterkova VA. Gormon rosta i shchitovidnaya zheleza. Available at: https://www.rostmaster.ru/lib/ gormonrost/gormonrost-0013.shtml. Accessed 26 Jan 2018. (In Russ).
  15. Molitvoslovova NN. Akromegaliya. In: Dedov II, editor. Klinicheskaya neyroendokrinologiya. Moscow: UP-Print; 2011. P. 137-69. (In Russ).
  16. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering seruv levels of GH and IGF-1 on mortality in acromegaly. Eur. J. Endocrinol. 2008;159:89-95. doi: 10.1530/EJE-08-0267.
  17. Melmed S, Casanueva FF, Cavag-nini F. Consensus Guidelines for Acromegaly Management. J. Clin. Endocr. Metab. 2002; 87:4054-8. doi: 10.1210/jc.2002-011841.
  18. Giustina A, Casanueva FF, Cavagnini F. Diagnosis and treatment of acromegaly complications. J. Endocrinol. Investigation. 2003; 26(12):1242-7.
  19. Yakovlev SA. Rol' dinamicheskoy kontrastnoy MRT v kompleksnoy luchevoy diagnostike i differentsial'noy diagnostike ob"emnykh obrazovaniy golovnogo mozga, raspolozhennykh po sredney linii [dissertation]. Saint-Petersburg; 2009. Avaiable at: http://medical-diss.com/medicina/rol-dinamiche-skoy-kontrastnoy-mrt-v-kompleksnoy-luchevoy-diagnostike-i-differentsialnoy-diagnostike-obem-nyh-obrazovaniy-g. Accessed 15 Jan 2018. (In Russ).
  20. Lobanov IA, Lavrenyuk AN, Niki-tin DN. Magnitno-rezonansnaya diagnostika adenom gipofiza. Meditsinskiy al'manakh. 2011; 1:104-7. (In Russ).
  21. Katznelson L, Atkinson JLD, Cook DM, et al. Medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocrine practice. 2011; 17(4):1-44.
  22. Lenzi J, Lapadula G, Damico T. Evaluation of trans-sphenoidal surgery in pituitary GH-secreting micro- and macroadenomas: a comparison between microsurgical and endoscopic approach. J. Neurosurg Sci. 2015; 59(1):8-11.
  23. Sytyy VP, Gonchar AA, Sytyy YuV. Adenomy gipofiza: istoriya, rasprostra-nennost', klinika, diagnostika, lechenie. Problemy zdorov'ya i ekologii. 2010; 3(25):41-50. (In Russ).
  24. Molitvoslovova NN, Marova EI, Yushkov PV. Khirurgicheskoe lechenie akro-megalii: kliniko-morfologicheskie oso-ben-nosti somatotropinom, opredelyayushchie posleoperatsionnyy prognoz. In: Vysokie meditsinskie tekhnologii v endokrinologii: 5-y Vserossiyskiy kongress po endokrinologii. Moscow; 2006. P. 411. (In Russ).
  25. Azizyan VN, Grigor'ev AYu, Ivashchenko OB, et.al. Intraoperatsionnoe krovoizliyanie v adenomu gipofiza kak prichina remissii akromegalii Endocrine surgery. 2011; 1:39-44. (In Russ).
  26. Grigor'ev AYu, Azizyan VN, Dedov II. Endoskopicheskaya khirurgiya adenom gipofiza: prakticheskoe rukovodstvo dlya vrachey. Moscow; 2011. (In Russ).
  27. Atsiferov MB, Pronin VS, Alek-seeva TM, et. al. Nastoyashchee i budushchee farmakoterapii akromegalii. Farmateka. 2012; 16:20-8. (In Russ).
  28. Mel'nichenko GA, Pronin VS. Sov-remennye skhemy farmakoterapii akrome-galii. Vrach. 2008;8:9-13. (In Russ).
  29. Shimon I, Yan X, Taylor JE. Soma-tostatin receptor (SSTR) subtype-selective analogueues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin. Invest. 1997; 100:2386-92.
  30. Marova EI, Mel'nichenko GA, Mo-litvoslovova NN. Klinicheskaya effektivnost' analoguea somatostatina dlitel'nogo deystviya Oktreotida-depo u bol'nykh akromegaliey. Farmateka. 2007;11:66-9. (In Russ).
  31. Vilar L, Czepielewsk MA, Naves LA, et al. Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr Pract. 2007;13(4);396-402.
  32. Cozzi R, Attanasio R, Lodrini S. Cabergoline addition to depot somatostatin analogueues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol. 2004;61:209-15.
  33. Marova EI, Mel'nichenko GA, Molitvoslovova NN. Klinicheskaya effektiv-nost' analoguea somatostatina dlitel'nogo deystviya Oktreotida-depo u bol'nykh akro-megaliey. Problems of endocrinology. 2011; 1:46-59. (In Russ).
  34. Marova EI, Mel'nichenko GA, Mo-litvoslovova NN. Klinicheskaya effektivnost' analoguea somatostatina dlitel'nogo deystviya Oktreotida-depo u bol'nykh akromegaliey. Vestnik RAMN. 2012; 8:7-13. (In Russ).
  35. Marova EI, Avakyan MR, Pod-lyashchuk EL. Rezul'taty distantsionnoy gamma-terapii u bol'nykh s akromegaliey. Problems of endocrinology. 1991; 37(1):22-5. (In Russ).
  36. Ilicheva VN, Ushakov BN. Effects of ionizing radiation on the energy exchange in different cerebral cortex. Rossijskiy mediko-biologicheskiy vestnik imeni akademika I.P. Pavlova. 2013; 21(1):30-6. (In Russ). doi: 10.17816/PAVLOVJ2013130-36.
  37. Titova L.Ju., Aristarhov V.G., Aristarhov R.V., Puzin D.A. Laser therapy in the treatment of infertility and menstrual function against the background of autoimmune thyroiditis. Nauka molodykh (Eruditio Juvenium). 2017;5(2):291-7. (In Russ). doi: 10.23888/HMJ20172291-297.

Copyright (c) 2018 Zhulidova A.U., Dubinina I.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies